Funds and ETFs Cosmo Pharmaceuticals N.V.

Equities

COPN

NL0011832936

Pharmaceuticals

Market Closed - Swiss Exchange 11:31:30 2024-04-26 am EDT 5-day change 1st Jan Change
71.6 CHF -0.69% Intraday chart for Cosmo Pharmaceuticals N.V. +0.28% +40.67%

ETFs positioned on Cosmo Pharmaceuticals N.V.

Name Weight AuM 1st Jan change Investor Rating
0.00% 10 M€ -3.35% -
0.00% 773 M€ -.--% -
0.00% 34 M€ +2.14% -
Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Bowel Diseases, Colon Infections, and products to reduce the incidence of Colorectal Cancer (CRC) by increasing the detection of cancerous and pre-cancerous lesions during colonoscopy. Products which it has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers’ diarrhoea (TD), Methylene Blue MMX, which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Winlevi for the treatment of acne. Its therapeutic focus is on the oral and endoscopic treatment of colon diseases.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
73.32 EUR
Average target price
95.38 EUR
Spread / Average Target
+30.08%
Consensus
  1. Stock Market
  2. Equities
  3. COPN Stock
  4. Funds and ETFs Cosmo Pharmaceuticals N.V.